Astrana Health, Inc. Reports First Quarter 2026 Results
Rhea-AI Summary
Astrana Health (NASDAQ: ASTH) reported Q1 2026 results: total revenue $965.1M (+56% YoY), adjusted EBITDA $66.3M (+82% YoY), net income $14.4M (+116% YoY) and free cash flow $64.1M (+372% YoY). The company said ~80% of Care Partners capitation revenue and ~40% of consolidated membership are now in full-risk arrangements. Guidance reiterated for 2026: total revenue $3.8B–$4.1B and adjusted EBITDA $250M–$280M; Q2 revenue guidance $965M–$1,000M and adjusted EBITDA $65M–$70M.
Positive
- Total revenue +56% YoY to $965.1M
- Adjusted EBITDA +82% YoY to $66.3M
- Free cash flow +372% YoY to $64.1M
- ~80% of Care Partners capitation revenue converted to full-risk
Negative
- Care Partners operating income down 11% vs prior year quarter
- Care delivery segment reported an operating loss in Q1 2026
News Market Reaction – ASTH
In the May 8 session, ASTH gained 8.92%, reflecting a notable positive market reaction. Argus tracked a peak move of +20.7% during that session. Our momentum scanner triggered 18 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 06 | Q3 2025 earnings | Neutral | -23.5% | Q3 2025 results with strong growth but updated timing on full‑risk contracts. |
| Aug 07 | Q2 2025 earnings | Positive | +30.9% | Strong Q2 growth, closing Prospect Health acquisition and reiterating 2025 guidance. |
| May 08 | Q1 2025 earnings | Neutral | -11.1% | Robust revenue growth offset by lower net income and EPS versus prior year. |
| Nov 07 | Q3 2024 earnings | Negative | -20.5% | Revenue growth but declining net income and adjusted EBITDA with updated guidance. |
| Aug 07 | Q2 2024 earnings | Positive | +1.1% | Strong Q2 growth, higher net income and adjusted EBITDA plus expansion initiatives. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings releases have driven sizable moves, generally aligned with the tone of results, with both strong rallies and sharp selloffs following prior reports.
Over the last several earnings cycles, Astrana has consistently reported rapid revenue growth, often above 35–40% year over year, while profitability and guidance updates have varied. Positive quarters like Q2 2025 and Q2 2024 saw constructive price reactions, whereas mixed or more complex updates, such as Q3 2025 and Q3 2024, coincided with double‑digit declines. Today’s Q1 2026 report continues the pattern of strong top-line expansion and rising adjusted EBITDA within that evolving trajectory.
Key Terms
adjusted ebitda financial
free cash flow financial
capitation medical
full-risk arrangements financial
medicare advantage medical
net leverage financial
patient safety excellence award medical
variable interest entities financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company to Host Conference Call on Thursday, May 7, 2026, at 2:30 p.m. PT/5:30 p.m. ET
- Reports total revenue of
$965.1 million 56% year over year - Reports adjusted EBITDA(1) of
$66.3 million 82% year over year and free cash flow(2) of$64.1 million 372% year over year
"We had a strong start to 2026, delivering disciplined growth, strong medical cost performance, continued operating leverage, and early performance from new full-risk contracts in line with our expectations," said Brandon Sim, President and Chief Executive Officer of Astrana Health. "In an increasingly dynamic healthcare environment, we believe advantage will accrue to organizations that can integrate care delivery, data, and financial accountability into a single operating system. Astrana has built exactly that: a proprietary healthcare operating platform that enables us to embed AI and workflow orchestration directly into clinical and operational workflows across the enterprise. Combined with our longitudinal patient relationships and data continuity, our infrastructure allows us to translate AI into durable clinical and economic value while continuing to improve patient outcomes, operating efficiency, and scalability. We believe Astrana is well positioned to continue widening that advantage over time."
Financial Highlights for First Quarter Ended March 31, 2026:
All comparisons are to the three months ended March 31, 2025 unless otherwise stated.
- Total revenue of
$965.1 million 56% from$620.4 million - Care Partners revenue of
$909.7 million 51% from$601.0 million - Net income attributable to Astrana of
$14.4 million 116% from$6.7 million - Earnings per share ("EPS") - diluted of
$0.29 107% from$0.14 - Adjusted EBITDA(1) of
$66.3 million 82% from$36.4 million - Adjusted EPS - diluted(3) of
$0.74 76% from$0.42 - Net cash provided by operating activities of
$68.1 million 309% from$16.6 million - Free cash flow(2) of
$64.1 million 372% from$13.6 million
(1) | See "Reconciliation of Net Income to EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin" and "Use of Non-GAAP Financial Measures" below for additional information. |
(2) | See reconciliation provided with the condensed consolidated statements of cash flow and "Use of Non-GAAP Financial Measures" below for additional information. |
(3) | See "Reconciliation of Net Income to Adjusted Net Income Attributable to Astrana and Adjusted EPS - Diluted" and "Use of Non-GAAP Financial Measures" below for additional information. |
Recent Operating Highlights
- Delivered on its commitment to convert key contracts to full-risk arrangements, with approximately
80% of Care Partners capitation revenue and approximately40% of consolidated membership now in full-risk arrangements. - Launched Astrana's delegated full-risk model with a payer partner in
Texas , expanding Medicare Advantage membership in the market to more than 14,000 members. - Continued deleveraging ahead of schedule, with net leverage declining to approximately 2.3x on a pro forma trailing twelve-month basis and to 2.2x based on the midpoint of the Company's full-year guidance.
- Foothill Regional Medical Center ("FRMC") received Healthgrades' 2026 Patient Safety Excellence Award™ for the fourth consecutive year and was named among Healthgrades' America's 100 Best Hospitals for Joint Replacement in 2026. FRMC also received the Healthgrades Joint Replacement Excellence Award for the second consecutive year, reflecting continued strength in clinical quality and patient outcomes.
Segment Results for three months ended March 31, 2026:
All comparisons are to the three months ended March 31, 2025 unless otherwise stated.
Three Months Ended March 31, 2026 | ||||||||||||||||||||||||
(in thousands) | Care | Care | Care | Intersegment | Corporate | Consolidated | ||||||||||||||||||
Total revenues | $ | 909,703 | $ | 85,077 | $ | 87,745 | $ | (117,425) | $ | — | $ | 965,100 | ||||||||||||
% change vs. prior year quarter | 51 | % | 155 | % | 122 | % | ||||||||||||||||||
Cost of services | 785,531 | 72,544 | 48,704 | (47,423) | — | 859,356 | ||||||||||||||||||
General and administrative expenses | 72,546 | 14,374 | 17,259 | (69,974) | 27,532 | 61,737 | ||||||||||||||||||
Depreciation and amortization | 12,170 | 1,122 | 1,629 | — | 558 | 15,479 | ||||||||||||||||||
Total expenses | 870,247 | 88,040 | 67,592 | (117,397) | 28,090 | 936,572 | ||||||||||||||||||
Income (loss) from operations | $ | 39,456 | $ | (2,963) | $ | 20,153 | $ | (28) | (1) | $ | (28,090) | $ | 28,528 | |||||||||||
% change vs. prior year quarter | (11) | % | (5) | % | 470 | % | ||||||||||||||||||
(1) | Loss from operations for the intersegment elimination represents sublease income between segments. Sublease income is presented within other income, which is not presented in the table. |
2026 Guidance:
Astrana is providing the following guidance for total revenue and Adjusted EBITDA for the quarter ending June 30, 2026 and reiterating guidance for the year ending December 31, 2026 based on the Company's existing business, current view of existing market conditions, and assumptions.
Three Months Ending | Year Ending | |||||||||||||||
Guidance Range | Guidance Range | |||||||||||||||
($ in millions) | Low | High | Low | High | ||||||||||||
Total revenue | $ | 965 | $ | 1,000 | $ | 3,800 | $ | 4,100 | ||||||||
Adjusted EBITDA | $ | 65 | $ | 70 | $ | 250 | $ | 280 | ||||||||
Free cash flow | $ | 105 | $ | 132.5 | ||||||||||||
See "Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA," "Guidance Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow," and "Use of Non-GAAP Financial Measures" below for additional information. There can be no assurance that actual amounts will not be materially higher or lower than these expectations. See "Forward-Looking Statements" below for additional information.
Conference Call and Webcast Information:
Astrana will host a conference call at 2:30 p.m. PT/5:30 p.m. ET today (Thursday, May 7, 2026), during which management will discuss the results of the first quarter ended March 31, 2026. To participate in the conference call, please use the following dial-in numbers about 5 minutes prior to the scheduled conference call time:
+1 (877) 858-9810 | |
International (Toll): | +1 (201) 689-8517 |
The conference call can also be accessed via webcast at: https://event.choruscall.com/mediaframe/webcast.html?webcastid=HHhCPjaF
An accompanying slide presentation will be available in PDF format on the "IR Calendar" page of the Company's website (https://ir.astranahealth.com/news-events/ir-calendar) after issuance of the earnings release and will be furnished as an exhibit to Astrana's current report on Form 8-K to be filed with the SEC, accessible at www.sec.gov.
Those who are unable to attend the live conference call may access the recording at the above webcast link, which will be made available shortly after the conclusion of the call.
Note About Consolidated Entities
The Company consolidates entities in which it has a controlling financial interest. The Company consolidates subsidiaries in which it holds, directly or indirectly, more than
About Astrana Health, Inc.
Astrana Health is a physician-centric, AI-powered healthcare company committed to delivering high-quality, patient-centered care. Built from the physician's perspective, Astrana combines its scalable care delivery infrastructure, proprietary technology platform, and aligned provider networks to enable proactive, preventive care at scale - improving patient outcomes, enhancing patient experiences, supporting provider well-being, and driving greater value across the healthcare system.
Today, Astrana supports more than 20,000 providers and approximately 1.55 million patients in value-based care arrangements through its affiliated provider networks, management services organization, and integrated care delivery clinics spanning primary, specialty, and ancillary care. Together, Astrana is building the healthcare system we all deserve - one that delivers better care, better experiences, and better outcomes for all. For more information, visit www.astranahealth.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements about the Company's guidance for the quarter ending June 30, 2026 and the year ending December 31, 2026, ability to meet operational goals, ability to meet expectations in deployment of care coordination and management capabilities, ability to decrease cost of care while improving quality and outcomes, ability to deliver sustainable revenue and EBITDA growth as well as long-term value, ability to respond to the changing environment, statements about the Company's liquidity, and successful completion and implementation of strategic growth plans, acquisition strategy, and merger integration efforts, as well as statements regarding the material weakness in internal control over financial reporting and the Company's ability to remediate such material weakness in a timely manner. Forward-looking statements reflect current views with respect to future events and financial performance and therefore cannot be guaranteed. Such statements are based on the current expectations and certain assumptions of the Company's management, and some or all of such expectations and assumptions may not materialize or may vary significantly from actual results. Actual results may also vary materially from forward-looking statements due to risks, uncertainties and other factors, known and unknown, including the risk factors described from time to time in the Company's reports to the SEC, including, without limitation the risk factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent quarterly reports on Form 10-Q. Any forward-looking statements made by the Company in this release speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.
FOR MORE INFORMATION, PLEASE CONTACT:
Carolyne Sohn, Investor Relations
investors@astranahealth.com
ASTRANA HEALTH, INC. | ||||||||
CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||||
(IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA) | ||||||||
March 31, | December 31, | |||||||
(Unaudited) | ||||||||
Assets | ||||||||
Current assets | ||||||||
Cash and cash equivalents | $ | 478,383 | $ | 429,474 | ||||
Receivables, net (including amounts from related parties) | 467,395 | 374,465 | ||||||
Income taxes receivable | — | 1,799 | ||||||
Other receivables | 28,017 | 26,385 | ||||||
Prepaid expenses and other current assets | 25,647 | 26,264 | ||||||
Loans receivable | 4,658 | 4,926 | ||||||
Total current assets | 1,004,100 | 863,313 | ||||||
Non-current assets | ||||||||
Property and equipment, net | 59,546 | 57,332 | ||||||
Intangible assets, net | 257,118 | 270,968 | ||||||
Goodwill | 874,799 | 865,305 | ||||||
Income taxes receivable, net of current portion | 26,220 | 26,220 | ||||||
Loans receivable, net of current portion | 49,068 | 48,724 | ||||||
Investments in other entities – equity method | 27,257 | 25,637 | ||||||
Operating lease right-of-use assets | 33,933 | 35,738 | ||||||
Other assets | 26,786 | 25,424 | ||||||
Total non-current assets | 1,354,727 | 1,355,348 | ||||||
Total assets (1) | $ | 2,358,827 | $ | 2,218,661 | ||||
Liabilities, Mezzanine Deficit, and Stockholders' Equity | ||||||||
Current liabilities | ||||||||
Accounts payable and accrued expenses | $ | 221,389 | $ | 195,912 | ||||
Fiduciary accounts payable | 3,706 | 3,524 | ||||||
Income taxes payable | 2,507 | — | ||||||
Medical liabilities | 439,259 | 335,705 | ||||||
Operating lease liabilities | 7,557 | 7,809 | ||||||
Current portion of long-term debt | 47,865 | 47,865 | ||||||
Other liabilities | 23,086 | 24,458 | ||||||
Total current liabilities | 745,369 | 615,273 | ||||||
Non-current liabilities | ||||||||
Deferred tax liability | 7,399 | 5,491 | ||||||
Operating lease liabilities, net of current portion | 30,006 | 31,552 | ||||||
Long-term debt, net of current portion and deferred financing costs | 979,764 | 990,904 | ||||||
Other long-term liabilities | 18,833 | 17,107 | ||||||
Total non-current liabilities | 1,036,002 | 1,045,054 | ||||||
Total liabilities (1) | 1,781,371 | 1,660,327 | ||||||
Mezzanine deficit | ||||||||
Non-controlling interest in Allied Physicians of | (237,739) | (234,962) | ||||||
Stockholders' equity | ||||||||
Preferred stock, | — | — | ||||||
Common stock, | 49 | 49 | ||||||
Additional paid-in capital | 477,508 | 470,863 | ||||||
Retained earnings | 322,711 | 308,379 | ||||||
Total stockholders' equity | 800,268 | 779,291 | ||||||
Non-controlling interests | 14,927 | 14,005 | ||||||
Total equity | 815,195 | 793,296 | ||||||
Total liabilities, mezzanine deficit, and stockholders' equity | $ | 2,358,827 | $ | 2,218,661 | ||||
(1) | The Company's condensed consolidated balance sheets include the assets and liabilities of its consolidated VIEs. The condensed consolidated balance sheets include (a) total assets of |
ASTRANA HEALTH, INC. | ||||||||
CONDENSED CONSOLIDATED STATEMENTS OF INCOME | ||||||||
(IN THOUSANDS, EXCEPT SHARE AND PER SHARE AMOUNTS) | ||||||||
(UNAUDITED) | ||||||||
Three Months Ended | ||||||||
2026 | 2025 | |||||||
Revenue | ||||||||
Capitation, net | $ | 892,908 | $ | 583,963 | ||||
Risk pool settlements and incentives | 12,486 | 14,491 | ||||||
Management fee income | 15,685 | 2,310 | ||||||
Fee-for-service, net | 37,831 | 14,890 | ||||||
Other revenue | 6,190 | 4,736 | ||||||
Total revenue | 965,100 | 620,390 | ||||||
Operating expenses | ||||||||
Cost of services, excluding depreciation and amortization | 859,356 | 549,061 | ||||||
General and administrative expenses | 61,737 | 43,897 | ||||||
Depreciation and amortization | 15,479 | 6,849 | ||||||
Total expenses | 936,572 | 599,807 | ||||||
Income from operations | 28,528 | 20,583 | ||||||
Other (expense) income | ||||||||
Income (loss) from equity method investments | 1,720 | (867) | ||||||
Interest expense | (16,101) | (7,308) | ||||||
Interest income | 3,816 | 2,312 | ||||||
Unrealized gain (loss) on investments | 1,084 | (44) | ||||||
Other income (loss) | 662 | (5,072) | ||||||
Total other expense, net | (8,819) | (10,979) | ||||||
Income before provision for income taxes | 19,709 | 9,604 | ||||||
Provision for income taxes | 6,578 | 3,383 | ||||||
Net income | 13,131 | 6,221 | ||||||
Net loss attributable to non-controlling interests | (1,305) | (471) | ||||||
Net income attributable to Astrana Health, Inc. | $ | 14,436 | $ | 6,692 | ||||
Earnings per share – basic | $ | 0.30 | $ | 0.14 | ||||
Earnings per share – diluted | $ | 0.29 | $ | 0.14 | ||||
Weighted average shares of common stock outstanding – basic | 48,853,678 | 48,470,682 | ||||||
Weighted average shares of common stock outstanding – diluted | 49,054,135 | 48,850,666 | ||||||
ASTRANA HEALTH, INC. | ||||||||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||||
(IN THOUSANDS) | ||||||||
(UNAUDITED) | ||||||||
Three Months Ended | ||||||||
2026 | 2025 | |||||||
Cash flows from operating activities | ||||||||
Net income | $ | 13,131 | $ | 6,221 | ||||
Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||
Depreciation and amortization | 15,479 | 6,849 | ||||||
Amortization of debt issuance cost | 1,134 | 691 | ||||||
Share-based compensation | 9,895 | 7,811 | ||||||
Non-cash lease expense | 2,005 | 1,287 | ||||||
Deferred tax | 1,907 | (358) | ||||||
Change in fair value of contingent consideration liabilities | 581 | 1,407 | ||||||
Other | (2,564) | 729 | ||||||
Changes in operating assets and liabilities, net of business combinations | 26,488 | (8,010) | ||||||
Net cash provided by operating activities | 68,056 | 16,627 | ||||||
Cash flows from investing activities | ||||||||
Purchases of property and equipment | (4,000) | (3,070) | ||||||
Other | 1,156 | 676 | ||||||
Net cash used in investing activities | (2,844) | (2,394) | ||||||
Cash flows from financing activities | ||||||||
Dividends paid | (104) | (5,455) | ||||||
Borrowings on debt | — | 412,000 | ||||||
Repayment of debt | (11,967) | (428,232) | ||||||
Deferred financing cost | — | (17,241) | ||||||
Taxes paid from net share settlement of restricted stock | (1,172) | (4,052) | ||||||
Repurchase of treasury shares | (2,906) | — | ||||||
Other | 189 | (1,190) | ||||||
Net cash used in financing activities | (15,960) | (44,170) | ||||||
Net increase (decrease) in cash, cash equivalents, and restricted cash | 49,252 | (29,937) | ||||||
Cash, cash equivalents, and restricted cash, beginning of period | 434,045 | 289,101 | ||||||
Cash, cash equivalents, and restricted cash, end of period | $ | 483,297 | $ | 259,164 | ||||
Supplemental disclosures of cash flow information | ||||||||
Cash paid for income taxes | (1) | $ | 4,338 | |||||
Cash paid for interest | $ | 14,723 | $ | 7,360 | ||||
Supplemental disclosures of non-cash investing and financing activities | ||||||||
Right-of-use assets obtained in exchange for operating lease liabilities | $ | 350 | $ | 5,729 | ||||
Dividend paid in the form of common stock | $ | — | $ | 21,935 | ||||
(1) | Following the adoption of ASC 2023-09 "Income Taxes (Topics 740): Improvements to Income Tax Disclosures", cash paid for income taxes is presented net of tax refunds, for the quarter ended March 31, 2026, under Item 1 of the Company's Quarterly Report on Form 10-Q. |
The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets that sum to the total amounts of cash, cash equivalents, and restricted cash shown in the condensed consolidated statements of cash flows (in thousands):
March 31, | ||||||||
2026 | 2025 | |||||||
Cash and cash equivalents | $ | 478,383 | $ | 258,517 | ||||
Restricted cash (1) | 4,914 | 647 | ||||||
Total cash, cash equivalents, and restricted cash shown in the statement of cash | $ | 483,297 | $ | 259,164 | ||||
(1) | Restricted cash is included in other assets on the condensed consolidated balance sheets. |
Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow | |||||||||
Three Months Ended | |||||||||
(in thousands) | 2026 | 2025 | |||||||
Net cash provided by operating activities | $ | 68,056 | $ | 16,627 | |||||
Purchases of property and equipment | (4,000) | (3,070) | |||||||
Free cash flow | $ | 64,056 | $ | 13,557 | |||||
Reconciliation of Net Income to EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin
Set forth below are reconciliations of Net Income to EBITDA and Adjusted EBITDA, as well as the reconciliations to Adjusted EBITDA margin for the three months ended March 31, 2026 and 2025. The Company defines Adjusted EBITDA margin as Adjusted EBITDA over total revenue.
Three Months Ended | |||||||||
(in thousands) | 2026 | 2025 | |||||||
Net income | $ | 13,131 | $ | 6,221 | |||||
Interest expense | 16,101 | 7,308 | |||||||
Interest income | (3,816) | (2,312) | |||||||
Provision for income taxes | 6,578 | 3,383 | |||||||
Depreciation and amortization | 15,479 | 6,849 | |||||||
EBITDA | 47,473 | 21,449 | |||||||
(Income) loss from equity method investments | (1,720) | 867 | |||||||
Other, net | 10,650 | (1) | 6,259 | (2) | |||||
Stock-based compensation | 9,895 | 7,811 | |||||||
Adjusted EBITDA | $ | 66,298 | $ | 36,386 | |||||
Total revenue | $ | 965,100 | $ | 620,390 | |||||
Adjusted EBITDA margin | 7 | % | 6 | % | |||||
(1) | Other, net, for the three months ended March 31, 2026, relates to an allowance on receivables that the Company plans to recover from the payer, post-acquisition integration costs, and severance fees incurred. |
(2) | Other, net, for the three months ended March 31, 2025, relates to debt issuance costs expensed in connection with our Second Amended and Restated Credit Facility, transaction costs for our acquisition of Prospect, certain costs for some of our acquisitions, non-cash changes related to change in the fair value of our call option and collar agreement, and severance fees incurred. |
Reconciliation of Net Income to Adjusted Net Income Attributable to Astrana and Adjusted EPS - Diluted
Set forth below are reconciliations of net income to adjusted net income attributable to Astrana as well as the reconciliation to adjusted EPS - diluted for the three months ended March 31, 2026 and 2025.
Three Months Ended | |||||||||
(in thousands, except for share and per share data) | 2026 | 2025 | |||||||
Net income | $ | 13,131 | $ | 6,221 | |||||
(Income) loss from equity method investments | (1,720) | 867 | |||||||
Other, net (1) | 10,650 | 6,259 | |||||||
Stock-based compensation | 9,895 | 7,811 | |||||||
Amortization of intangible assets attributable to acquisitions | 13,850 | 6,263 | |||||||
Tax adjustments | (7,525) | (2) | (4,602) | (3) | |||||
Adjusted net income attributable to non-controlling interests | (1,928) | (4) | (2,317) | (5) | |||||
Adjusted net income attributable to Astrana Health, Inc. | $ | 36,353 | $ | 20,502 | |||||
Weighted average shares of common stock outstanding – diluted | 49,054,135 | 48,850,666 | |||||||
Adjusted earnings per share - diluted | $ | 0.74 | $ | 0.42 | |||||
(1) | The components of other, net, as set forth in the table above, are described in the footnotes to the table under "Reconciliation of Net Income to EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin". Please see the footnotes to such table for additional information. |
(2) | Tax adjustments for the three months ended March 31, 2026, includes the tax effect for, at a |
(3) | Tax adjustments for the three months ended March 31, 2025, includes the tax effect for, at a |
(4) | Includes net loss attributable to non-controlling interests ("NCI") of |
(5) | Includes net loss attributable to NCI of |
Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA | ||||||||
Year Ending | ||||||||
Guidance Range | ||||||||
(in thousands) | Low | High | ||||||
Net income | $ | 54,000 | $ | 74,000 | ||||
Interest expense | 51,000 | 55,000 | ||||||
Provision for income taxes | 38,000 | 44,000 | ||||||
Depreciation and amortization | 65,000 | 65,000 | ||||||
EBITDA | 208,000 | 238,000 | ||||||
Income from equity method investments | (4,000) | (4,000) | ||||||
Other, net | 7,000 | 7,000 | ||||||
Stock-based compensation | 39,000 | 39,000 | ||||||
Adjusted EBITDA | $ | 250,000 | $ | 280,000 | ||||
The Company has not provided a quantitative reconciliation of EBITDA and Adjusted EBITDA for the quarter ending June 30, 2026 to the most comparable GAAP measure on a forward-looking basis within this press release because the Company is unable, without unreasonable efforts, to provide reconciling information with respect to certain line items that cannot be calculated for the three month period. These items, which could materially affect the computation of forward-looking GAAP net income, are inherently uncertain and depend on various factors, some of which are outside of the Company's control.
Guidance Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow | ||||||||
Year Ending | ||||||||
Guidance Range | ||||||||
(in thousands) | Low | High | ||||||
Net cash provided by operating activities | $ | 125,000 | $ | 145,000 | ||||
Cash used in purchases of property and equipment | (20,000) | (12,500) | ||||||
Free cash flow | $ | 105,000 | $ | 132,500 | ||||
Use of Non-GAAP Financial Measures
This press release contains the non-GAAP financial measures EBITDA, Adjusted EBITDA, Adjusted EBITDA margin, adjusted net income attributable to Astrana, and adjusted EPS - diluted, of which the most directly comparable financial measure presented in accordance with
We believe the presentation of these non-GAAP financial measures provides investors with relevant and useful information, as it allows investors to evaluate the operating performance of the business activities without having to account for differences recognized because of non-core or non-recurring financial information. When GAAP financial measures are viewed in conjunction with non-GAAP financial measures, investors are provided with a more meaningful understanding of our ongoing operating performance. In addition, these non-GAAP financial measures are among those indicators we use as a basis for evaluating operational performance, allocating resources, and planning and forecasting future periods. Non-GAAP financial measures are not intended to be considered in isolation, or as a substitute for, GAAP financial measures. Other companies may calculate EBITDA, Adjusted EBITDA, adjusted net income attributable to Astrana, adjusted EPS - diluted, and free cash flow differently, limiting the usefulness of these measures for comparative purposes. To the extent this press release contains historical or future non-GAAP financial measures, we have provided corresponding GAAP financial measures for comparative purposes. The reconciliations between certain GAAP and non-GAAP measures are provided above.
View original content to download multimedia:https://www.prnewswire.com/news-releases/astrana-health-inc-reports-first-quarter-2026-results-302766186.html
SOURCE Astrana Health, Inc.